The Possible Role of the Kynurenine Pathway in Adolescent Depression with Melancholic Features

Overview

Journal J Child Psychol Psychiatry

Specialties Psychiatry
Psychology

Date 2010 Apr 22

PMID 20406333

Citations 57

Authors

Vilma Gabbay

Rachel G Klein

Yisrael Katz

Sandra Mendoza

Leah E Guttman

Carmen M Alonso

James S Babb

Glenn S Hirsch

Leonard Liebes

Affiliations

Soon will be listed here.

Abstract

Background: Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups. This study addresses this issue by examining whether adolescent MDD with and without melancholic features (M-MDD and NonM-MDD) have distinct biological features in the kynurenine pathway (KP). The KP is initiated by pro-inflammatory cytokines via induction of the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades tryptophan (TRP) into kynurenine (KYN). KYN is further metabolized into neurotoxins linked to neuronal dysfunction in MDD. Hypotheses were that, compared to healthy controls and to NonM-MDD adolescents, adolescents with M-MDD would exhibit: (i) increased activation of the KP [i.e., increased KYN and KYN/TRP (reflecting IDO activity)]; (ii) greater neurotoxic loads [i.e., increased 3-hydroxyanthranilic acid (3-HAA, neurotoxin) and 3-HAA/KYN (reflecting production of neurotoxins)]; and (iii) decreased TRP. We also examined relationships between severity of MDD and KP metabolites.

Methods: Subjects were 20 adolescents with M-MDD, 30 adolescents with NonM-MDD, and 22 healthy adolescents. MDD episode duration had to be >or= 6 weeks and Children's Depression Rating Scale-Revised (CDRS-R) scores were >or= 36. Blood samples were collected at AM after an overnight fast and analyzed using high-performance liquid chromatography. Group contrasts relied on analysis of covariance based on ranks, adjusted for age, gender, and CDRS-R scores. Analyses were repeated excluding medicated patients. Fisher's protected least significant difference was used for multiple comparisons.

Results: As hypothesized, KYN/TRP ratios were elevated and TRP concentrations were reduced in adolescents with M-MDD compared to NonM-MDD adolescents (p = .001 and .006, respectively) and to healthy controls (p = .008 and .022, respectively). These findings remained significant when medicated patients were excluded from the analyses. Significant correlations were obtained exclusively in the M-MDD group between KYN and 3-HAA/KYN and CDRS-R.

Conclusions: Findings support the notion that adolescent M-MDD may represent a biologically distinct clinical syndrome.

Citing Articles

The major biogenic amine metabolites in mood disorders.

Yang J, Yuan M, Zhang W Front Psychiatry. 2024; 15:1460631.

PMID: 39381610 PMC: 11458445. DOI: 10.3389/fpsyt.2024.1460631.

Immunological correlates of suicidality among adolescents with internalizing symptoms.

Roske C, Nguyen T, Schwartz J, Erulker A, Nie K, Xie H Brain Behav Immun Health. 2024; 41:100866.

PMID: 39350953 PMC: 11439560. DOI: 10.1016/j.bbih.2024.100866.

The correlation of inflammation, tryptophan-kynurenine pathway, and suicide risk in adolescent depression.

Yang S, Han J, Ye Z, Zhou H, Yan Y, Han D Eur Child Adolesc Psychiatry. 2024; .

PMID: 39287643 DOI: 10.1007/s00787-024-02579-4.

Biomarker-Guided Tailored Therapy in Major Depression.

Perna G, Spiti A, Torti T, Dacco S, Caldirola D Adv Exp Med Biol. 2024; 1456:379-400.

PMID: 39261439 DOI: 10.1007/978-981-97-4402-2_19.

Changes in tryptophan breakdown associated with response to multimodal treatment in depression.

Reininghaus E, Lenger M, Schonthaler E, Fellendorf F, Stross T, Schwarz M Front Psychiatry. 2024; 15:1380620.

PMID: 38974918 PMC: 11224482. DOI: 10.3389/fpsyt.2024.1380620.

References

Ambrosini P, Bennett D, Cleland C, Haslam N . Taxonicity of adolescent melancholia: a categorical or dimensional construct?. J Psychiatr Res. 2002; 36(4):247-56. DOI: 10.1016/s0022-3956(02)00011-0. View

Curry J, Rohde P, Simons A, Silva S, Vitiello B, Kratochvil C . Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006; 45(12):1427-39. DOI: 10.1097/01.chi.0000240838.78984.e2. View

Badawy A . Plasma free tryptophan revisited: what you need to know and do before measuring it. J Psychopharmacol. 2008; 24(6):809-15. DOI: 10.1177/0269881108098965. View

Myint A, Kim Y, Verkerk R, Scharpe S, Steinbusch H, Leonard B . Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2006; 98(1-2):143-51. DOI: 10.1016/j.jad.2006.07.013. View

Ryan N, Ambrosini P, Rabinovich H, Robinson D, Nelson B, Iyengar S . The clinical picture of major depression in children and adolescents. Arch Gen Psychiatry. 1987; 44(10):854-61. DOI: 10.1001/archpsyc.1987.01800220016003. View

Sanacora G, Gueorguieva R, Epperson C, Wu Y, Appel M, Rothman D . Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004; 61(7):705-13. DOI: 10.1001/archpsyc.61.7.705. View

Capuron L, Ravaud A, Neveu P, Miller A, Maes M, Dantzer R . Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002; 7(5):468-73. DOI: 10.1038/sj.mp.4000995. View

Maes M, Scharpe S, Meltzer H, Okayli G, Bosmans E, DHondt P . Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 1994; 54(2):143-60. DOI: 10.1016/0165-1781(94)90003-5. View

Wichers M, Koek G, Robaeys G, Verkerk R, Scharpe S, Maes M . IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2004; 10(6):538-44. DOI: 10.1038/sj.mp.4001600. View

10.

Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M . Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology. 2001; 26(8):797-808. DOI: 10.1016/s0306-4530(01)00030-0. View

11.

Petty F, Kramer G, Gullion C, Rush A . Low plasma gamma-aminobutyric acid levels in male patients with depression. Biol Psychiatry. 1992; 32(4):354-63. DOI: 10.1016/0006-3223(92)90039-3. View

12.

Gabbay V, Liebes L, Katz Y, Liu S, Mendoza S, Babb J . The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 34(1):37-44. PMC: 2815014. DOI: 10.1016/j.pnpbp.2009.09.015. View

13.

Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P . Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36(7):980-8. DOI: 10.1097/00004583-199707000-00021. View

14.

Irwin M, Miller A . Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007; 21(4):374-83. DOI: 10.1016/j.bbi.2007.01.010. View

15.

Capuron L, Neurauter G, Musselman D, Lawson D, Nemeroff C, Fuchs D . Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry. 2003; 54(9):906-14. DOI: 10.1016/s0006-3223(03)00173-2. View

16.

Klein D . Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry. 1974; 31(4):447-54. DOI: 10.1001/archpsyc.1974.01760160005001. View

17.

Cowen P, Parry-Billings M, Newsholme E . Decreased plasma tryptophan levels in major depression. J Affect Disord. 1989; 16(1):27-31. DOI: 10.1016/0165-0327(89)90051-7. View

18.

Gabbay V, Klein R, Alonso C, Babb J, Nishawala M, De Jesus G . Immune system dysregulation in adolescent major depressive disorder. J Affect Disord. 2008; 115(1-2):177-82. PMC: 2770721. DOI: 10.1016/j.jad.2008.07.022. View

19.

Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M . Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry. 2001; 6(4):475-80. DOI: 10.1038/sj.mp.4000872. View

20.

Sapko M, Guidetti P, Yu P, Tagle D, Pellicciari R, Schwarcz R . Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol. 2005; 197(1):31-40. DOI: 10.1016/j.expneurol.2005.07.004. View